Critical Comparison: GAMCO Investors (NYSE:GAMI) & Dominari (NASDAQ:DOMH)

GAMCO Investors (NYSE:GAMI) and Dominari (NASDAQ:DOMH) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Insider & Institutional Ownership

3.3% of GAMCO Investors shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 81.2% of GAMCO Investors shares are held by insiders. Comparatively, 9.7% of Dominari shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares GAMCO Investors and Dominari’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GAMCO Investors	$235.87 million	2.55	$60.21 million	$2.40	10.10
Dominari	$2.04 million	5.87	-$22.88 million	($4.64)	-0.44

GAMCO Investors has higher revenue and earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than GAMCO Investors, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GAMCO Investors and Dominari’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GAMCO Investors	25.81%	34.27%	23.66%
Dominari	-721.11%	-38.40%	-35.22%

Analyst Recommendations

This is a summary of current ratings and recommmendations for GAMCO Investors and Dominari, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GAMCO Investors	0	0	0	0	N/A
Dominari	0	0	0	0	N/A

Volatility and Risk

GAMCO Investors has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Dominari has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.

Summary

GAMCO Investors beats Dominari on 9 of the 11 factors compared between the two stocks.

About GAMCO Investors

GAMCO Investors, Inc. is a publicly owned holding investment manager. The firm also provides wealth management, investment advisory, institutional research, brokerage, dealer, underwriting, and distribution services to its clients. It provides its services to individuals including high net worth individuals, corporate pension and profit-sharing plans, foundations, endowments, jointly trust plans, municipalities, and investment companies. The firm, through its subsidiaries, manages separate client-focused equity, fixed income, and balanced portfolios. It also launches equity, fixed income, and balanced mutual funds and manages equity mutual funds for its clients. Through its subsidiaries the firm invests in the public equity and fixed income markets across the globe. It invests in value stocks of companies. The firm employs fundamental analysis with a focus on bottom-up stock picking approach to create its portfolios. It conducts in-house research to make its investments. The firm was founded in 1976 and is based in Rye, New York with additional offices in Greenwich, Connecticut; Bannockburn, Illinois; and Tokyo, Japan. GAMCO Investors, Inc. operates as a subsidiary of Ggcp Holdings Llc.

About Dominari

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.